RT Journal Article
SR Electronic
T1 Development of an amplicon-based sequencing approach in response to the global emergence of human monkeypox virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.14.22280783
DO 10.1101/2022.10.14.22280783
A1 Chen, Nicholas F.G.
A1 Chaguza, Chrispin
A1 Gagne, Luc
A1 Doucette, Matthew
A1 Smole, Sandra
A1 Buzby, Erika
A1 Hall, Joshua
A1 Ash, Stephanie
A1 Harrington, Rachel
A1 Cofsky, Seana
A1 Clancy, Selina
A1 Kapsak, Curtis J.
A1 Sevinsky, Joel
A1 Libuit, Kevin
A1 Park, Daniel J.
A1 Hemarajata, Peera
A1 Garrigues, Jacob M.
A1 Green, Nicole M.
A1 Sierra-Patev, Sean
A1 Carpenter-Azevedo, Kristin
A1 Huard, Richard C.
A1 Pearson, Claire
A1 Incekara, Kutluhan
A1 Nishimura, Christina
A1 Huang, Jian Ping
A1 Gagnon, Emily
A1 Reever, Ethan
A1 Razeq, Jafar
A1 Muyombwe, Anthony
A1 Borges, Vítor
A1 Ferreira, Rita
A1 Sobral, Daniel
A1 Duarte, Silvia
A1 Santos, Daniela
A1 Vieira, Luís
A1 Gomes, João Paulo
A1 Aquino, Carly
A1 Savino, Isabella M.
A1 Felton, Karinda
A1 Bajwa, Moneeb
A1 Hayward, Nyjil
A1 Miller, Holly
A1 Naumann, Allison
A1 Allman, Ria
A1 Greer, Neel
A1 Fall, Amary
A1 Mostafa, Heba H.
A1 McHugh, Martin P.
A1 Maloney, Daniel M.
A1 Dewar, Rebecca
A1 Kenicer, Juliet
A1 Parker, Abby
A1 Mathers, Katharine
A1 Wild, Jonathan
A1 Cotton, Seb
A1 Templeton, Kate E.
A1 Churchwell, George
A1 Lee, Philip A.
A1 Pedrosa, Maria
A1 McGruder, Brenna
A1 Schmedes, Sarah
A1 Plumb, Matthew R.
A1 Wang, Xiong
A1 Barcellos, Regina Bones
A1 Godinho, Fernanda M.S.
A1 Salvato, Richard Steiner
A1 Ceniseros, Aimee
A1 Breban, Mallery I.
A1 Grubaugh, Nathan D.
A1 Gallagher, Glen R.
A1 Vogels, Chantal B.F.
YR 2023
UL http://medrxiv.org/content/early/2023/01/13/2022.10.14.22280783.abstract
AB The 2022 multi-country monkeypox (mpox) outbreak concurrent with the ongoing COVID-19 pandemic has further highlighted the need for genomic surveillance and rapid pathogen whole genome sequencing. While metagenomic sequencing approaches have been used to sequence many of the early mpox infections, these methods are resource intensive and require samples with high viral DNA concentrations. Given the atypical clinical presentation of cases associated with the outbreak and uncertainty regarding viral load across both the course of infection and anatomical body sites, there was an urgent need for a more sensitive and broadly applicable sequencing approach. Highly multiplexed amplicon-based sequencing (PrimalSeq) was initially developed for sequencing of Zika virus, and later adapted as the main sequencing approach for SARS-CoV-2. Here, we used PrimalScheme to develop a primer scheme for human monkeypox virus that can be used with many sequencing and bioinformatics pipelines implemented in public health laboratories during the COVID-19 pandemic. We sequenced clinical samples that tested presumptive positive for human monkeypox virus with amplicon-based and metagenomic sequencing approaches. We found notably higher genome coverage across the virus genome, with minimal amplicon drop-outs, in using the amplicon-based sequencing approach, particularly in higher PCR cycle threshold (lower DNA titer) samples. Further testing demonstrated that Ct value correlated with the number of sequencing reads and influenced the percent genome coverage. To maximize genome coverage when resources are limited, we recommend selecting samples with a PCR cycle threshold below 31 Ct and generating 1 million sequencing reads per sample. To support national and international public health genomic surveillance efforts, we sent out primer pool aliquots to 10 laboratories across the United States, United Kingdom, Brazil, and Portugal. These public health laboratories successfully implemented the human monkeypox virus primer scheme in various amplicon sequencing workflows and with different sample types across a range of Ct values. Thus, we show that amplicon based sequencing can provide a rapidly deployable, cost-effective, and flexible approach to pathogen whole genome sequencing in response to newly emerging pathogens. Importantly, through the implementation of our primer scheme into existing SARS-CoV-2 workflows and across a range of sample types and sequencing platforms, we further demonstrate the potential of this approach for rapid outbreak response.Competing Interest StatementNDG is a consultant for Tempus Labs and the National Basketball Association for work related to COVID-19. All other authors declare no competing interests.Clinical Protocols https://dx.doi.org/10.17504/protocols.io.5qpvob1nbl4o/v2 Funding StatementThis publication was made possible by CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH) awarded to CBFV. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH. INSA was partially funded by the HERA project (Grant/2021/PHF/23776) supported by the European Commission through the European Centre for Disease Control.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As part of this study, we sequenced remnant clinical samples that tested presumptive positive for monkeypox virus. Ethical oversight for each institution is indicated in Table 1. All data were de-identified prior to sharing and sample codes as included in the manuscript are not known outside the research groups.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data are available on NCBI Sequence Read Archive (SRA), GenBank, and GISAID (see accession numbers in Supplementary Table 2). All other data are included in the manuscript and the supplementary files.